Crossmark

Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers

Crossref DOI link: https://doi.org/10.1038/s41698-024-00615-9

Published Online: 2024-05-31

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nussbaum, Daniel P.

Martz, Colin A.

Waters, Andrew M. https://orcid.org/0000-0002-6058-5878
Barrera, Alejandro

Liu, Annie

Rutter, Justine C. https://orcid.org/0000-0002-0851-0887
Cerda-Smith, Christian G.

Stewart, Amy E.

Wu, Chao

Cakir, Merve

Levandowski, Cecilia B.

Kantrowitz, David E.

McCall, Shannon J. https://orcid.org/0000-0003-3957-061X
Pierobon, Mariaelena https://orcid.org/0000-0003-2084-1029
Petricoin, Emanuel F. III

Joshua Smith, J. https://orcid.org/0000-0003-2538-5456
Reddy, Timothy E.

Der, Channing J. https://orcid.org/0000-0002-7751-2747
Taatjes, Dylan J.

Wood, Kris C. https://orcid.org/0000-0002-5887-2253
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA263593, R01CA207083, F32CA180569, R01CA175747, U01CA199235, P01CA203657, R35CA232113, 5F32CA268527)

U.S. Department of Health & Human Services | NIH | National Cancer Institute

U.S. Department of Defense (W81XWH2110362)

Duke University (N/A (Start-Up Funds))

U.S. Department of Health & Human Services | NIH | National Cancer Institute

American Cancer Society (PF 18-061)

U.S. Department of Health & Human Services | NIH | National Cancer Institute

U.S. Department of Health & Human Services | NIH | National Cancer Institute

U.S. Department of Health & Human Services | NIH | National Cancer Institute

U.S. Department of Health & Human Services | NIH | National Cancer Institute

U.S. Department of Health & Human Services | NIH | National Cancer Institute
License Information

Text and Data Mining valid from 2024-05-31

Version of Record valid from 2024-05-31
More Information

Article History

Received: 30 October 2023

Accepted: 3 May 2024

First Online: 31 May 2024

Competing interests

: K.C.W. is a founder, consultant, and equity holder at Tavros Therapeutics and Celldom and has performed consulting work for Guidepoint Global, Bantam Pharmaceuticals, and Apple Tree Partners. C.J.D. is an advisory board member for Deciphera Pharmaceuticals, Mirati Therapeutics, Reactive Biosciences, Revolution Medicines and SHY Therapeutics, has received research funding support from Deciphera Pharmaceuticals, Mirati Therapeutics, Reactive Biosciences, Revolution Medicines and SpringWorks Therapeutics, and has consulted for Day One Biotherapeutics, Eli Lilly, Jazz Therapeutics, Ribometrix, Sanofi, and Turning Point Therapeutics. The remaining authors declare no competing interests. JJS received travel support for fellow education from Intuitive Surgical (August 2015). He also served as a clinical advisor for Guardant Health (March 2019) and as a clinical advisor for Foundation Medicine (April 2022). He served as a consultant and speaker for Johnson and Johnson (May 2022). And he serves as a clinical advisor and consultant for GlaxoSmithKline (2023-24).

: All co-authors have fulfilled authorship criteria as determined by Nature portfolio.

Document is current

Any future updates will be listed below